We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.15%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
+$170M
Cap. Flow
+$163M
Cap. Flow %
46.98%
Top 10 Hldgs %
43.57%
Holding
90
New
39
Increased
14
Reduced
5
Closed
27

Top Buys

1
ACOR
Acorda Therapeutics
ACOR
+$8.81M
2
EW icon
Edwards Lifesciences
EW
+$8.72M
3
BIIB icon
Biogen
BIIB
+$7.91M
4
BLUE
bluebird bio
BLUE
+$7.43M
5
CNMD icon
CONMED
CNMD
+$7.41M

Top Sells

1
CELG
Celgene Corp
CELG
+$6.74M
2
PACB icon
Pacific Biosciences
PACB
+$5.95M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.68M
4
SAGE
Sage Therapeutics
SAGE
+$5.34M
5
IHF icon
iShares US Healthcare Providers ETF
IHF
+$4.82M

Sector Composition

1 Healthcare 56.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$40.2M 11.62%
350,000
+275,000
+367% +$31M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$21.6M 6.25%
400,000
+180,000
+82% +$9.86M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$20.9M 6.05%
+100,000
New +$20.7M
GWPH
4
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$11.9M 3.44%
+130,000
New +$10.9M
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11M 3.17%
215,000
+95,000
+79% +$4.72M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$10.5M 3.03%
90,000
+50,000
+125% +$7.09M
NUVA
7
DELISTED
NuVasive, Inc.
NUVA
$8.96M 2.59%
150,000
+80,000
+114% +$4.32M
MDT icon
8
Medtronic
MDT
$106B
$8.68M 2.51%
100,000
+73,422
+276% +$5.94M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.5B
$8.56M 2.47%
110,000
+70,000
+175% +$5.95M
EW icon
10
Edwards Lifesciences
EW
$49.4B
$8.48M 2.45%
+255,000
New +$8.72M
CNMD icon
11
CONMED
CNMD
$1.3B
$8.35M 2.41%
+175,000
New +$7.41M
ACOR
12
DELISTED
Acorda Therapeutics
ACOR
$8.29M 2.39%
+2,708
New +$8.81M
BSX icon
13
CALL
Boston Scientific
BSX
$65.4B
$8.18M 2.36%
+350,000
New +$7.57M
BSX icon
14
Boston Scientific
BSX
$65.4B
$7.59M 2.19%
325,000
-125,000
-28% -$2.7M
SIOX
15
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.38M 2.13%
+71,875
New +$7.18M
BLUE
16
DELISTED
bluebird bio
BLUE
$7.36M 2.13%
+13,124
New +$7.43M
BIIB icon
17
Biogen
BIIB
$30.4B
$7.25M 2.1%
+30,000
New +$7.91M
SPNC
18
DELISTED
Spectranetics Corp
SPNC
$7.02M 2.03%
375,000
+25,000
+7% +$440K
CLVS
19
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$6.86M 1.98%
+500,000
New +$7.31M
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
$6.17M 1.78%
450,000
+431,500
+2,332% +$6.31M
NVRO
21
DELISTED
NEVRO CORP.
NVRO
$5.9M 1.7%
80,000
+5,000
+7% +$339K
SRPT icon
22
PUT
Sarepta Therapeutics
SRPT
$1.82B
$5.72M 1.65%
+300,000
New +$5.56M
NBIX icon
23
Neurocrine Biosciences
NBIX
$17.2B
$5.68M 1.64%
+125,000
New +$5.75M
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.23B
$5.67M 1.64%
700,000
+450,000
+180% +$2.83M
KTWO
25
DELISTED
K2M Group Holdings, Inc
KTWO
$5.43M 1.57%
+350,000
New +$4.94M
1
2 3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Ghost Tree Capital held 90 positions worth $346M, up 96% from $177M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital deployed $163M of net new capital in Q2 2016, opening 39 new positions and adding to 14 existing holdings. Its largest new stake was Acorda Therapeutics: 2,708 shares worth $8.29M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $6.74M trimmed.

  • Ghost Tree Capital's largest Q2 2016 buy was Acorda Therapeutics: 2,708 shares worth $8.29M.
  • Ghost Tree Capital added most to Alexion Pharmaceuticals in Q2 2016, an estimated $7.09M increase.
  • Ghost Tree Capital's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $6.74M.
  • Ghost Tree Capital fully exited Pacific Biosciences in Q2 2016, selling an estimated $5.95M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $346M portfolio in Q2 2016.
  • Ghost Tree Capital opened 39 new positions and closed 27 in Q2 2016.
  • Ghost Tree Capital's portfolio value rose 96% quarter-over-quarter to $346M.

Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.